- Home
- ALZN
ALZN
Alzamend Neuro Inc.
as 07-26-2024 4:00pm EST
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | ATLANTA |
| Market Cap: | 3.0M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 15.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -18.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.27 - $73.20 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Alzamend Neuro Inc. (ALZN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| AULT MILTON C III | ALZN | Director10% Owner | Apr 19 '24 | Buy | $0.69 | 1,000 | $688.20 | 771,699 | SEC Form 4 |
| AULT MILTON C III | ALZN | Director10% Owner | Apr 1 '24 | Buy | $0.91 | 334 | $304.24 | 770,699 | SEC Form 4 |
| AULT MILTON C III | ALZN | Director10% Owner | Mar 28 '24 | Buy | $1.06 | 2,000 | $2,127.00 | 770,365 | SEC Form 4 |
| AULT MILTON C III | ALZN | Director10% Owner | Jan 5 '24 | Buy | $1.02 | 5,000 | $5,092.50 | 768,365 | SEC Form 4 |
| AULT MILTON C III | ALZN | 10% Owner | Dec 22 '23 | Buy | $0.92 | 200 | $184.84 | 166,866 | SEC Form 4 |
| AULT MILTON C III | ALZN | 10% Owner | Dec 22 '23 | Buy | $0.90 | 500 | $450.00 | 26,032 | SEC Form 4 |
Latest Alzamend Neuro Inc. News
ALZN Breaking Stock News: Dive into ALZN Ticker-Specific Updates for Smart Investing
MT Newswires
14 days ago
Alzamend Neuro Board Approves 1-for-10 Reverse Stock Split
Business Wire
14 days ago
Alzamend Neuro Announces Reverse Stock Split
Journal-News, Hamilton, Ohio
2 months ago
Retiring ODW executive to be first inductee in Hamilton Business Hall of Fame
TechCrunch
2 months ago
Cat-sitting startup Meowtel clawed its way to profitability despite trouble raising from dog-focused VCs
Motley Fool
2 months ago
Once-in-a-Generation Investment Opportunity: Why You Should Buy Carnival Stock Now
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Simply Wall St.
2 months ago
It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend
Bloomberg
2 months ago
Saudis Said to Hand About 60% of Aramco Offer to Foreigners
Compare ALZN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALZN Alzamend Neuro Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.